Gender differences in stage-adjusted bladder cancer survival

N. Aydin Mungan, Katja K H Aben, Mark P. Schoenberg, Otto Visser, Jan Willem W Coebergh, J. Alfred Witjes, Lambertus A L M Kiemeney

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Objectives. Gender differences have been observed in the prognosis of patients with bladder cancer. It has also been suggested that these differences are caused by a worse stage distribution at diagnosis among women. The purpose of this study was to evaluate whether women with bladder cancer have a worse prognosis even after adjustment for disease stage at first presentation. Methods. Data on patients with bladder cancer diagnosed between 1973 and 1996 and registered by one of the nine population-based Surveillance, Epidemiology, and End Results (SEER) cancer registries in the United States (n = 80,305) were obtained from the National Cancer Institute public domain SEER*Stat 2.0 package. Similar data on patients with bladder cancer diagnosed between 1987 and 1994 and registered by two population-based registries in the Netherlands (n = 1722) were obtained through the Comprehensive Cancer Centers, Amsterdam and South. Survival rates adjusted for mortality owing to other causes (ie, relative survival) were calculated for men and women within each category of the American Joint Committee on Cancer (SEER data) and TNM (Netherlands data) stage groupings. Results. In the United States, the 5-year relative survival rate of male patients with bladder cancer was calculated to be 79.5% (95% confidence interval 79.0% to 80.0%). Among women, the 5-year relative survival rate was significantly worse: 73.1% (95% confidence interval 72.2% to 74.0%). The male versus female 5-year survival rate among stage groups I, II, III, and IV was 96.5% versus 93.7%, 65.5% versus 59.6%, 58.8% versus 49.6%, and 27.1% versus 15.2%, respectively. The (sparser) data from the Netherlands were less conclusive. Women with Stage II and Stage IV disease fared worse than men but the reverse seemed to be true in Stage I disease. Conclusions. Female patients with bladder cancer have a worse prognosis than male patients. It is unlikely that the difference can explained entirely by the more frequent diagnosis of higher stages at first presentation among women. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)876-880
Number of pages5
JournalUrology
Volume55
Issue number6
DOIs
StatePublished - Jun 2000
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Survival
Survival Rate
Netherlands
Epidemiology
Registries
Population Surveillance
Confidence Intervals
Neoplasms
National Cancer Institute (U.S.)
Public Sector
Mortality
Population

ASJC Scopus subject areas

  • Urology

Cite this

Mungan, N. A., Aben, K. K. H., Schoenberg, M. P., Visser, O., Coebergh, J. W. W., Witjes, J. A., & Kiemeney, L. A. L. M. (2000). Gender differences in stage-adjusted bladder cancer survival. Urology, 55(6), 876-880. https://doi.org/10.1016/S0090-4295(00)00523-9

Gender differences in stage-adjusted bladder cancer survival. / Mungan, N. Aydin; Aben, Katja K H; Schoenberg, Mark P.; Visser, Otto; Coebergh, Jan Willem W; Witjes, J. Alfred; Kiemeney, Lambertus A L M.

In: Urology, Vol. 55, No. 6, 06.2000, p. 876-880.

Research output: Contribution to journalArticle

Mungan, NA, Aben, KKH, Schoenberg, MP, Visser, O, Coebergh, JWW, Witjes, JA & Kiemeney, LALM 2000, 'Gender differences in stage-adjusted bladder cancer survival', Urology, vol. 55, no. 6, pp. 876-880. https://doi.org/10.1016/S0090-4295(00)00523-9
Mungan NA, Aben KKH, Schoenberg MP, Visser O, Coebergh JWW, Witjes JA et al. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000 Jun;55(6):876-880. https://doi.org/10.1016/S0090-4295(00)00523-9
Mungan, N. Aydin ; Aben, Katja K H ; Schoenberg, Mark P. ; Visser, Otto ; Coebergh, Jan Willem W ; Witjes, J. Alfred ; Kiemeney, Lambertus A L M. / Gender differences in stage-adjusted bladder cancer survival. In: Urology. 2000 ; Vol. 55, No. 6. pp. 876-880.
@article{6321f2ead118408cbf797205283a5bdc,
title = "Gender differences in stage-adjusted bladder cancer survival",
abstract = "Objectives. Gender differences have been observed in the prognosis of patients with bladder cancer. It has also been suggested that these differences are caused by a worse stage distribution at diagnosis among women. The purpose of this study was to evaluate whether women with bladder cancer have a worse prognosis even after adjustment for disease stage at first presentation. Methods. Data on patients with bladder cancer diagnosed between 1973 and 1996 and registered by one of the nine population-based Surveillance, Epidemiology, and End Results (SEER) cancer registries in the United States (n = 80,305) were obtained from the National Cancer Institute public domain SEER*Stat 2.0 package. Similar data on patients with bladder cancer diagnosed between 1987 and 1994 and registered by two population-based registries in the Netherlands (n = 1722) were obtained through the Comprehensive Cancer Centers, Amsterdam and South. Survival rates adjusted for mortality owing to other causes (ie, relative survival) were calculated for men and women within each category of the American Joint Committee on Cancer (SEER data) and TNM (Netherlands data) stage groupings. Results. In the United States, the 5-year relative survival rate of male patients with bladder cancer was calculated to be 79.5{\%} (95{\%} confidence interval 79.0{\%} to 80.0{\%}). Among women, the 5-year relative survival rate was significantly worse: 73.1{\%} (95{\%} confidence interval 72.2{\%} to 74.0{\%}). The male versus female 5-year survival rate among stage groups I, II, III, and IV was 96.5{\%} versus 93.7{\%}, 65.5{\%} versus 59.6{\%}, 58.8{\%} versus 49.6{\%}, and 27.1{\%} versus 15.2{\%}, respectively. The (sparser) data from the Netherlands were less conclusive. Women with Stage II and Stage IV disease fared worse than men but the reverse seemed to be true in Stage I disease. Conclusions. Female patients with bladder cancer have a worse prognosis than male patients. It is unlikely that the difference can explained entirely by the more frequent diagnosis of higher stages at first presentation among women. Copyright (C) 2000 Elsevier Science Inc.",
author = "Mungan, {N. Aydin} and Aben, {Katja K H} and Schoenberg, {Mark P.} and Otto Visser and Coebergh, {Jan Willem W} and Witjes, {J. Alfred} and Kiemeney, {Lambertus A L M}",
year = "2000",
month = "6",
doi = "10.1016/S0090-4295(00)00523-9",
language = "English (US)",
volume = "55",
pages = "876--880",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Gender differences in stage-adjusted bladder cancer survival

AU - Mungan, N. Aydin

AU - Aben, Katja K H

AU - Schoenberg, Mark P.

AU - Visser, Otto

AU - Coebergh, Jan Willem W

AU - Witjes, J. Alfred

AU - Kiemeney, Lambertus A L M

PY - 2000/6

Y1 - 2000/6

N2 - Objectives. Gender differences have been observed in the prognosis of patients with bladder cancer. It has also been suggested that these differences are caused by a worse stage distribution at diagnosis among women. The purpose of this study was to evaluate whether women with bladder cancer have a worse prognosis even after adjustment for disease stage at first presentation. Methods. Data on patients with bladder cancer diagnosed between 1973 and 1996 and registered by one of the nine population-based Surveillance, Epidemiology, and End Results (SEER) cancer registries in the United States (n = 80,305) were obtained from the National Cancer Institute public domain SEER*Stat 2.0 package. Similar data on patients with bladder cancer diagnosed between 1987 and 1994 and registered by two population-based registries in the Netherlands (n = 1722) were obtained through the Comprehensive Cancer Centers, Amsterdam and South. Survival rates adjusted for mortality owing to other causes (ie, relative survival) were calculated for men and women within each category of the American Joint Committee on Cancer (SEER data) and TNM (Netherlands data) stage groupings. Results. In the United States, the 5-year relative survival rate of male patients with bladder cancer was calculated to be 79.5% (95% confidence interval 79.0% to 80.0%). Among women, the 5-year relative survival rate was significantly worse: 73.1% (95% confidence interval 72.2% to 74.0%). The male versus female 5-year survival rate among stage groups I, II, III, and IV was 96.5% versus 93.7%, 65.5% versus 59.6%, 58.8% versus 49.6%, and 27.1% versus 15.2%, respectively. The (sparser) data from the Netherlands were less conclusive. Women with Stage II and Stage IV disease fared worse than men but the reverse seemed to be true in Stage I disease. Conclusions. Female patients with bladder cancer have a worse prognosis than male patients. It is unlikely that the difference can explained entirely by the more frequent diagnosis of higher stages at first presentation among women. Copyright (C) 2000 Elsevier Science Inc.

AB - Objectives. Gender differences have been observed in the prognosis of patients with bladder cancer. It has also been suggested that these differences are caused by a worse stage distribution at diagnosis among women. The purpose of this study was to evaluate whether women with bladder cancer have a worse prognosis even after adjustment for disease stage at first presentation. Methods. Data on patients with bladder cancer diagnosed between 1973 and 1996 and registered by one of the nine population-based Surveillance, Epidemiology, and End Results (SEER) cancer registries in the United States (n = 80,305) were obtained from the National Cancer Institute public domain SEER*Stat 2.0 package. Similar data on patients with bladder cancer diagnosed between 1987 and 1994 and registered by two population-based registries in the Netherlands (n = 1722) were obtained through the Comprehensive Cancer Centers, Amsterdam and South. Survival rates adjusted for mortality owing to other causes (ie, relative survival) were calculated for men and women within each category of the American Joint Committee on Cancer (SEER data) and TNM (Netherlands data) stage groupings. Results. In the United States, the 5-year relative survival rate of male patients with bladder cancer was calculated to be 79.5% (95% confidence interval 79.0% to 80.0%). Among women, the 5-year relative survival rate was significantly worse: 73.1% (95% confidence interval 72.2% to 74.0%). The male versus female 5-year survival rate among stage groups I, II, III, and IV was 96.5% versus 93.7%, 65.5% versus 59.6%, 58.8% versus 49.6%, and 27.1% versus 15.2%, respectively. The (sparser) data from the Netherlands were less conclusive. Women with Stage II and Stage IV disease fared worse than men but the reverse seemed to be true in Stage I disease. Conclusions. Female patients with bladder cancer have a worse prognosis than male patients. It is unlikely that the difference can explained entirely by the more frequent diagnosis of higher stages at first presentation among women. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034078108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034078108&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(00)00523-9

DO - 10.1016/S0090-4295(00)00523-9

M3 - Article

C2 - 10840099

AN - SCOPUS:0034078108

VL - 55

SP - 876

EP - 880

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -